tbuckley/cabot-search huggingface dataset:
Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study
Authors: Wendy N Nembhard, Xinyu Tang, Zhuopei Hu, Stewart MacLeod, Zachary Stowe, Daniel Webber
Journal: BMJ (2017)

Objective To evaluate whether the association between maternal periconceptional use of selective serotonin reuptake inhibitors (SSRIs) and increased risk of congenital heart defects in offspring is modified by maternal or infant genetic variants in folate, homocysteine, or transsulfuration pathways.Design Population based study. DNA from mothers, fathers, and infants was genotyped with an Illumina GoldenGate custom single nucleotide polymorphism panel. A hybrid design based on a log linear model was used to calculate relative risks and Bayesian false discovery probabilities (BFDP) to identify polymorphisms associated with congenital heart defects modified by SSRI use.Data sources Data from the US National Birth Defects Prevention Study on 1180 liveborn infants with congenital heart defects and 1644 controls, born 1997-2008.Main outcome measures Cases included infants with selected congenital heart defects and control infants had no major defects. SSRI use was obtained from telephone interviews with mothers.Results For women who reported taking SSRIs periconceptionally, maternal SHMT1 (rs9909104) GG and AGgenotypes were associated with a 5.9 and 2.4 increased risk of select congenital heart defects in offspring, respectively, versus the AA genotype (BFDP=0.69). Compared with the AA genotype, BHMT (rs492842 and rs542852) GG and AG genotypes were associated with twice the riskof congenital heart defects (BFDP=0.74 and 0.79, respectively). MGST1 (rs2075237) CC and ACgenotypes were associated with an increased risk compared with the GG genotype (8.0 and 2.8, respectively; BFDP=0.79). Single nucleotide polymorphism in infant genes in the folate (MTHFS rs12438477), homocysteine (TRDMT1 rs6602178 and GNMT rs11752813) and transsulfuration (GSTP1 rs7941395 and MGST1 rs7294985) pathways were also associated with an increased risk of congenital heart defects.Conclusions Common maternal or infant genetic variants in folate, homocysteine, or transsulfuration pathways are associated with an increased risk of certain congenital heart defects among children of women taking SSRIs during cardiogenesis.
Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans
Authors: Arianna Calcinotto, Maurilio Ponzoni, Roberto Ria, Matteo Grioni, Elena Cattaneo, Isabella Villa, Maria Teresa Sabrina Bertilaccio, Marta Chesi, Alessandro Rubinacci, Giovanni Tonon, Peter Leif Bergsagel, Angelo Vacca, Matteo Bellone
Journal: Blood (2014)
Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Authors: Yuankai Shi, Mei Dong, Jun Zhu, Daobin Zhou, Huiqiang Huang, Ping Tu, Weijing Zhang, Xiaonan Hong, Xielan Zhao, Jianfang Sun, Yuehua Liu, Lugui Qiu, ZhiXiang Shen, Jifeng Feng, Xiaoyan Ke
Journal: Blood (2015)
Protein-free formation of bone-like apatite: New insights into the key role of carbonation
Authors: Alix C. Deymier, Arun K. Nair, Baptiste Depalle, Zhao Qin, Kashyap Arcot, Christophe Drouet, Claude H. Yoder, Markus J. Buehler, Stavros Thomopoulos, Guy M. Genin, Jill D. Pasteris
Journal: Biomaterials (2017)
Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study
Authors: Noopur Raje, Parameswaran N Hari, Dan T. Vogl, Sundar Jagannath, Robert Z. Orlowski, Jeffrey G Supko, Patricia Stephenson, Simon S Jones, Catherine Wheeler, Sagar Lonial
Journal: Blood (2012)
Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140
Authors: Stuti Mehta, D. Alexander Cronkite, Megha Basavappa, Tahnee L. Saunders, Fatemeh Adiliaghdam, Hajera Amatullah, Sara A. Morrison, Jose D. Pagan, Robert M. Anthony, Pierre Tonnerre, Georg M. Lauer, James C. Lee, Sreehaas Digumarthi, Lorena Pantano, Shannan J. Ho Sui, Fei Ji, Ruslan Sadreyev, Chan Zhou, Alan C. Mullen, Vinod Kumar, Yang Li, Cisca Wijmenga, Ramnik J. Xavier, Terry K. Means, Kate L. Jeffrey
Journal: Science Immunology (2017)

The epigenetic reader SP140, which is polymorphic in Crohn’s disease patients, regulates transcriptional programs in macrophages.
Population Pharmacokinetics and Pharmacodynamics of AG-519, a Pyruvate Kinase Activator for the Treatment of Pyruvate Kinase Deficiency, in Human Healthy Volunteers
Authors: Kha Le, Marvin Cohen, Ann J Barbier, Elizabeth Merica, Charles Kung, Penelope A Kosinski, Scott Biller, Hua Yang
Journal: Blood (2016)
Allocution Du Prof. H. Steck, Lausanne
Authors: G. Benedetti, P.C. Racamier, R. Schindler, W.Th. Winkler, Martti Siirala, A. Fuchs-Kamp, A. Storch, F.W. Beese, F. Meerwein, H. Bach, M. Sechehaye, K. Ernst, N. Elrod, Gerdhild von Staabs, Torsten Herner, Kauko Kaila, Georg Schwöbel, M. Boss
Journal: Psychotherapy and Psychosomatics (1957)
Highly Purified Hematopoietic Stem Cells Convert to Cells with Myoblast Characteristics before Forming Myotubes.
Authors: Mehrdad Abedi, Deborah A. Greer, Bethany M. Foster, Gerald A. Colvin, Delia A. Demers, Mark S. Dooner, Peter J. Quesenberry
Journal: Blood (2005)
Abstract IA04: Game theory and personalized cancer treatment
Authors: Robert H. Austin
Journal: Cancer Research (2017)

Abstract The presence of driver mutations and subsequent clonal expansion by Darwinian evolution does not explain dormancy and re-emergence of cancer from a community of cancer and host cells (including stromal and immune cells). Dormancy appears to be a slow-driven, interaction-dominated, threshold system which is poorly prognosed. At the simplest level, we view cancer cells interacting with host cells via complex, non-linear population dynamics, which can lead to very non-intuitive but perhaps deterministic and understandable progression dynamics of cancer. We explore here the dynamics of host-cancer cell populations in the presence of (1) payoffs gradients and (2) perturbation due to cell migration to determine to what extent the time-dependence of the populations can be quantitatively understood in spite of the underlying complexity of the individual agents. The population dynamics presented here provide a model system for the clinic to map the payoffs matrices and suggest new avenues to predict drug dosages. Citation Format: Robert H. Austin. Game theory and personalized cancer treatment. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr IA04.
Severe Adverse Events By First Line Tyrosine Kinase Inhibitors Decrease Survival Rate in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Shuichi Ota, Toshihiro Matsukawa, Satoshi Yamamoto, Shinichi Ito, Motohiro Shindo, Kazuya Sato, Takeshi Kondo, Tohru Takahashi, Tsutomu Sato, Yasutaka Kakinoki, Hajime Kobayashi, Mitsutoshi Kurosawa
Journal: Blood (2016)
Contents, Vol. 64, 1995
Authors: Gian Paolo Guaraldi, Emanuele Orlandi, Louis A. Gottschalk, Karl Burgoyne, Randolph Swartz, Jambur Ananth, K. Thunedborg, C.H. Black, P. Bech, Nancy J. Keuthen, Richard L. O'Sullivan, Joseph N. Ricciardi, David Shera, Cary R. Savage, Andrea S. Borgmann, Michael A. Jenike, Lee Baer, Paolo Boselli, Pier Luigi Tartoni, Randall S. Jorgensen, Kenneth Abdul-Karim, Todd A. Kahan, James J. Frankowski, Pio Enrico Ricci Bitti, Paola Gremigni, Giorgio Bertolotti, Anna Maria Zotti, Loma K. Flowers, Angela Zettler, Gabriele Duran, Sabine Waadt, Peter Herschbach, Friedrich Strian, Richard L. O'Sullivan, Nancy J. Keuthen, Caroline F. Hayday, Joseph N. Ricciardi, Lynn Buttolph, Michael A. Jenike, Lee Baer
Journal: Psychotherapy and Psychosomatics (1995)
Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib
Authors: Debora A Casolari, Diana G Iarossi, Carolyn M Butcher, Sarah C Bray, Wendy T Parker, Chris N Hahn, Susan Branford, Peter Bardy, Ian D Lewis, Hamish S Scott, Steven W Lane, David M Ross, Richard J D'Andrea
Journal: Blood (2014)
Association of tissue factor expression in squamous cell head and neck carcinomas with well-differentiated tumors.
Authors: Benjamin Jacobs, Xinmin Zhang, John P. Gaughan, Michael Bromberg
Journal: Journal of Clinical Oncology (2012)

e16022 Background: Tissue factor (TF) is a glycoprotein that initiates coagulation when complexed with factor VIIa. High levels of TF expression have been found in many cancers and correlated with tumor aggressiveness. TF has been shown to be expressed in head and neck squamous cell carcinomas (HNSCC) but the role of TF on cell function and prognosis are not known. The epidermal growth factor receptor (EGFR) is overexpressed in many HNSCC and EGFR and TF expression are highly correlated in some tumor types. Our goal was to correlate the expression of TF and EGFR in HNSCC with tumor cell differentiation and prognosis. Methods: Twenty biopsy specimens of squamous cell head and neck carcinomas were studied. Immunohistochemistry for TF, EGFR, and p16 was performed. Cases were scored based upon the staining intensity of tumor cells using a semiquantitative scale as negative, weakly (+), moderately (++) or strongly (+++) positive. Results: The tumor stages ranged from T1N0 to T4N3. Of the 20 specimens, 5 were well differentiated, 12 were of moderate differentiation, and 3 were poorly differentiated. Median survival was 23 months, median follow-up 73 months. TF was expressed in 75% (15/20) of tumors at varying levels. Moderate TF expression was found in 6 specimens, and 9 showed weak expression. None of the poorly differentiated tumors expressed TF, and there was a definite negative correlation between TF expression and tumor differentiation (Pearson r=--0.747, p=0.0002). There was no association between TF expression and survival (Log-Rank 0.3115, p=0.8558). All of the tumors analyzed expressed EGFR and there was no correlation between TF expression and EGFR expression. Overall, 25% (5/20) of tumors expressed p16, suggesting human papilloma virus infection. Conclusions: Results from this retrospective study indicate that well differentiated HNSCC express higher levels of TF than poorly differentiated tumors and that TF and EGFR expression are not tightly linked. Moreover, unlike other cancer sites, HNSCC TF expression did not appear to worsen overall patient survival, and was actually associated with more well-differentiated tumors.
Impact of Time to Lymphocyte Recovery on Survival Post Autologous Stem Cell Transplantation.
Authors: Fabio PS Santos, Joyce E Hyppolito, Vinicius B Grilo, Jairo Sobrinho, Andreza Alice Feitosa Ribeiro, Jose Mauro Kutner, Morgani Rodrigues, Claudia Bley, Guilherme Fleury Perini, Reijane Alves de Assis, Vicente Odone, Juliana F Fernandes, Fabio R. Kerbauy, Nelson Hamerschlak
Journal: Blood (2010)
Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy
Authors: Guillermo Montalban-Bravo, Ana Alfonso Pierola, Koichi Takahashi, Elias J. Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney D. DiNardo, Naval G. Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Sherry Pierce, Carlos E Bueso-Ramos, Keyur Patel, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2016)
High Response and Complete Remission Rates in Relapsed/Refractory Multiple Myeloma Treated with Bortezomib, Thalidomide, Dexamethasone and Zoledronic Acid (VTD-Z) Combination Therapy.
Authors: Gerrard Teoh, Daryl Tan, William Hwang, Liang Piu Koh, Charles Chuah, Heng Joo Ng
Journal: Blood (2005)
Rituximab - Inmunotherapy Combined with Chemotherapy, CHOP for the Treatment of Patients with Difusse Large B - Cell Lymphoma (DLBCL).
Authors: Jorge H. Milone, Fernando Bezares, Maria del Carmen Ardaiz, Dardo Riveros, Luis Palmer, Ider Cerutti, Alfredo Basso, Marta Gelemur, Carlos Cánepa, Gustavo Kusminsky, Marta Zerga
Journal: Blood (2005)
A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)
Authors: Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Michael Fennessy, Thomas C. Shea, Gary Spitzer, Izidore S Lossos, Mohamed A. Kharfan-Dabaja, Robin Joyce, Luis Fayad, Qiming Liao, Klaus Edvardsen, Steen Lisby, Craig H. Moskowitz
Journal: Blood (2011)
Social network architecture of human immune cells unveiled by quantitative proteomics
Authors: Jan C Rieckmann, Roger Geiger, Daniel Hornburg, Tobias Wolf, Ksenya Kveler, David Jarrossay, Federica Sallusto, Shai S Shen-Orr, Antonio Lanzavecchia, Matthias Mann, Felix Meissner
Journal: Nature Immunology (2017)
Alemtuzumab (CAMPATH-1H™) Is Effective Therapy for Hypereosinophilic Syndrome (HES).
Authors: Alfonso Quintas-Cardama, Ayalew Tefferi, Jorge Cortes, Animesh Pardanani, Farhad Ravandi-Kashani, Francis Giles, Pat Ault, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2006)
Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
Authors: James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger, David L. Rimm
Journal: Journal for ImmunoTherapy of Cancer (2017)

<h3>Background</h3> Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (PD-L1), highlighting the need for a more sensitive biomarker. We hypothesize that capacity to express PD-L1, as assessed by an assay for a PD-L1 transcription factor, interferon regulatory factor 1 (IRF-1), may better distinguish patients likely to benefit from anti-PD-1 immunotherapy. <h3>Methods</h3> Samples from 47 melanoma patients that received nivolumab, pembrolizumab, or combination ipilimumab/nivolumab at Yale New Haven Hospital from May 2013 to March 2016 were collected. Expression of IRF-1 and PD-L1 in archival pre-treatment formalin-fixed, paraffin-embedded tumor samples were assessed by the AQUA method of quantitative immunofluorescence. Objective radiographic response (ORR) and progression-free survival (PFS) were assessed using modified RECIST v1.1 criteria. <h3>Results</h3> Nuclear IRF-1 expression was higher in patients with partial or complete response (PR/CR) than in patients with stable or progressive disease (SD/PD) (<i>p =</i> 0.044). There was an insignificant trend toward higher PD-L1 expression in patients with PR/CR (<i>p =</i> 0.085). PFS was higher in the IRF-1-high group than the IRF-1-low group (<i>p =</i> 0.017), while PD-L1 expression had no effect on PFS (<i>p =</i> 0.83). In a subset analysis, a strong association with PFS is seen in patients treated with combination ipilimumab and nivolumab (<i>p =</i> 0.0051). <h3>Conclusions</h3> As a measure of PD-L1 expression capability, IRF-1 expression may be a more valuable predictive biomarker for anti-PD-1 therapy than PD-L1 itself.
The Long-term Effect of Acupuncture for Migraine Prophylaxis
Authors: Ling Zhao, Jiao Chen, Ying Li, Xin Sun, Xiaorong Chang, Hui Zheng, Biao Gong, Yinlan Huang, Mingxiao Yang, Xi Wu, Xuezhi Li, Fanrong Liang
Journal: JAMA Internal Medicine (2017)

The long-term prophylactic effects of acupuncture for migraine are uncertain.To investigate the long-term effects of true acupuncture compared with sham acupuncture and being placed in a waiting-list control group for migraine prophylaxis.This was a 24-week randomized clinical trial (4 weeks of treatment followed by 20 weeks of follow-up). Participants were randomly assigned to true acupuncture, sham acupuncture, or a waiting-list control group. The trial was conducted from October 2012 to September 2014 in outpatient settings at 3 clinical sites in China. A total of 249 participants 18 to 65 years old with migraine without aura based on the criteria of the International Headache Society, with migraine occurring 2 to 8 times per month.Participants in the true acupuncture and sham acupuncture groups received treatment 5 days per week for 4 weeks for a total of 20 sessions. Participants in the waiting-list group did not receive acupuncture but were informed that 20 sessions of acupuncture would be provided free of charge at the end of the trial.Participants used diaries to record migraine attacks. The primary outcome was the change in the frequency of migraine attacks from baseline to week 16. Secondary outcome measures included the migraine days, average headache severity, and medication intake every 4 weeks within 24 weeks.A total of 249 participants 18 to 65 years old were enrolled, and 245 were included in the intention-to-treat analyses. One hundred eighty-nine (77.1%) were women. Baseline characteristics were comparable across the 3 groups. The mean (SD) change in frequency of migraine attacks differed significantly among the 3 groups at 16 weeks after randomization (P < .001); the mean (SD) frequency of attacks decreased in the true acupuncture group by 3.2 (2.1), in the sham acupuncture group by 2.1 (2.5), and the waiting-list group by 1.4 (2.5); a greater reduction was observed in the true acupuncture than in the sham acupuncture group (difference of 1.1 attacks; 95% CI, 0.4-1.9; P = .002) and in the true acupuncture vs waiting-list group (difference of 1.8 attacks; 95% CI, 1.1-2.5; P < .001). Sham acupuncture was not statistically different from the waiting-list group (difference of 0.7 attacks; 95% CI, -0.1 to 1.4; P = .07).Among patients with migraine without aura, true acupuncture may be associated with long-term reduction in migraine recurrence compared with sham acupuncture or assigned to a waiting list.clinicaltrials.gov Identifier: NCT01687660.
Abstract PR07: A biosensor mouse to predict the dissociation and spread of pancreatic cancer
Authors: David Herrmann, Zahra Erami, Sean Warren, Max Nobis, Astrid Magenau, Morghan Lucas, Claire Vennin, Ewan J. McGhee, Wilfred Leung, Nadine Reischmann, Agata Mrowinska, Juliane P. Schwarz, Shereen Kadir, Saadia A. Karim, Andrew D. Campbell, David Gallego-Ortega, Jeffry Evans, Owen J. Sansom, Jennifer P. Morton, Kurt I. Anderson, Paul Timpson
Journal: Cancer Research (2017)

Abstract E-cadherin-mediated cell-cell junctions play a physical role in maintaining normal epithelial architecture. The disruption or deregulation of these adhesions in cancer can lead to the collapse of tumor epithelia that precedes invasion and subsequent metastasis. Here, we have generated an E-cadherin-GFP(FRAP) biosensor mouse, which enables intravital photobleaching and quantification of E-cadherin mobility in live tissue, without affecting normal biology. We demonstrate using FRAP or FLIP, the broad applications of this mouse to examine E-cadherin regulation in multiple tissues including mammary, brain, liver and kidney, while specifically monitoring E-cadherin mobility during disease progression in the pancreas. We assess E-cadherin stability in native pancreatic tissue, upon genetic manipulation involving Kras and p53 or in response to anti-invasive drug treatment, and reveal new insights into the dynamic remodeling of E-cadherin during in situ cancer progression. Photobleaching in the E-cadherin-GFP(FRAP) mouse correlate directly with epithelial integrity and mechanical strength making the biosensor mouse a valuable tool to fundamentally expand our understanding of E-cadherin-mediated events in native micro-environments. This abstract is also being presented as Poster B23. Citation Format: David Herrmann, Zahra Erami, Sean Warren, Max Nobis, Astrid Magenau, Morghan Lucas, Claire Vennin, Ewan J. McGhee, Wilfred Leung, Nadine Reischmann, Agata Mrowinska, Juliane P. Schwarz, Shereen Kadir, Saadia A. Karim, Andrew D. Campbell, David Gallego-Ortega, Jeffry Evans, Owen J. Sansom, Jennifer P. Morton, Kurt I. Anderson, Paul Timpson. A biosensor mouse to predict the dissociation and spread of pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr PR07.
Variation in surgeon payment for cancer resection.
Authors: Tasce Bongiovanni, Anthony W. Kim, Brigid K. Killelea, Simon P. Kim, Cary Philip Gross
Journal: Journal of Clinical Oncology (2015)

e17802 Background: Demand for price transparency in healthcare is growing, empowering employers and beneficiaries to better understand what they pay for services. Variation in surgeon payments for oncologic resection has not been well studied, especially in the private-payer sector. We therefore assessed (1) geographic variation of private payer expenditures to surgeons for cancer resection, (2) variation within geographical regions for these expenditures. Methods: We use data based on fee-for-service allowed amounts, billed by a mix of private-payer providers for the year 2013, obtained in partnership with Fair Health, Inc. FAIR Health (FH) is an independent, not-for-profit corporation that collects and compiles claims data from insurers nationwide. We selected surgical resections frequently used for treating breast, lung and prostate cancer with CPT codes for simple mastectomy (SM), open lobectomy (LB), and robotic radical prostatectomy (RP). We evaluated surgeon reimbursement, as derived by FH through an ‘allowed medical benchmark’ (AMB) based on the maximum allowable payments for the submitted procedure codes and relative value units of the procedure. The data is grouped into 491 geographical regions based on zip code. To assess variation across regions, we compared the median AMB between regions. To assess intra-region variability, we evaluated regional inter-quartile ranges of AMB. Results: For each surgical procedure, the surgeon’s median AMB varied substantially across regions: For SM, the median AMB ranged from $487 in the least expensive region to $1,364 in the costliest region. For LB the median AMB ranged from $498 to $5,047; for RP from $1,716 to $5,775. Even standard deviations for the 50thpercentile of AMB were high (LB $1,450, RP $1,173). There was also substantial variation within geographic regions. The AMB means of the 25th & 75thpercentile within regions were as follows: for SM $552 & $1,088, LB $997 & $3,061, and RP $2,350 & $3,567. Conclusions: We found a wide range of variation both across and within geographic regions in the allowed reimbursement for these common surgical procedures. Transparency about surgical payment may have a profound impact on patient and employer choice and facilitate future assessments of value in cancer care.
Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer
Authors: J Tchou, PJ Zhang, BL Levine, Y Zhao, J Matro, A DeMichele, C Amy, L Schuchter, G Plesa, RH Vonderheide, C June
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Deep-learning networks and the functional architecture of executive control
Authors: Richard P. Cooper
Journal: Behavioral and Brain Sciences (2017)

Lake et al. underrate both the promise and the limitations of contemporary deep learning techniques. The promise lies in combining those techniques with broad multisensory training as experienced by infants and children. The limitations lie in the need for such systems to possess functional subsystems that generate, monitor, and switch goals and strategies in the absence of human intervention.